Vir Biotechnology (VIR) closed at $11.30 on October 30, 2026, down 3.8% from the previous close, on volume of 1,143,513 shares (30-day average 1,914,776).
Data as of October 30, 2026.
30-Oct-2026
Vir Biotechnology appoints Topalian to board, boosts oversight
TipRanks (Wed, 28-Oct 8:57 AM ET)
Vir Biotechnology Announces Appointment of Suzanne Topalian to its Board of Directors
Business Wire (Wed, 28-Oct 8:30 AM ET)
Vir Biotechnology to Host Conference Call for Third Quarter 2026 Financial Results
Business Wire (Wed, 21-Oct 4:05 PM ET)
Business Wire (Wed, 14-Oct 8:30 AM ET)
Market Chameleon (Fri, 9-Oct 7:54 AM ET)
Market Chameleon (Thu, 8-Oct 5:34 AM ET)
Business Wire (Thu, 8-Oct 8:30 AM ET)
Vir Biotechnology Appoints David Liu as Chief Medical Officer
Business Wire (Wed, 7-Oct 8:30 AM ET)
Business Wire (Mon, 5-Oct 4:05 PM ET)
Vir Biotechnology Appoints Aziz Sawaf as Chief Financial Officer
Business Wire (Thu, 1-Oct 8:30 AM ET)
Vir Biotechnology Inc is a clinical-stage biopharmaceutical company focused on powering the immune system by discovering and developing medicines for serious infectious diseases and cancer. The company uses its capabilities in antibody discovery and engineering, coupled with its proprietary AI engine dAIsY system, and the PRO-XTEN masking platform, to quickly and effectively discover and optimize potential new medicines. Its clinical development pipeline consists of investigational therapies like Tobevibart + elebsiran targeting the hepatitis delta virus (HDV), preclinical antibody candidates targeting HIV, and VIR-5500, VIR-5818, VIR-5525, and 7 PRO-XTEN programs targeting multiple solid tumors. Currently, the company generates revenue mainly by issuing license rights and through grants.
Vir Biotechnology trades on the NASDAQ stock market under the symbol VIR.
As of October 30, 2026, VIR stock price declined to $11.30 with 1,143,513 million shares trading.
VIR has a beta of 1.34, meaning it tends to be more sensitive to market movements. VIR has a correlation of 0.09 to the broad based SPY ETF.
VIR has a market cap of $1.82 billion. This is considered a Small Cap stock.
Last quarter Vir Biotechnology reported $239 million in Revenue and $.47 earnings per share. This beat revenue expectation by $9 million and missed earnings estimates by -$.41.
In the last 3 years, VIR traded as high as $14.45 and as low as $4.16.
The top ETF exchange traded funds that VIR belongs to (by Net Assets): IJR, VTI, IWM, VB, XBI.
VIR has outperformed the market in the last year with a price return of +90.6% while the SPY ETF gained +12.3%. VIR has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +27.0% and +13.5%, respectively, while the SPY returned +2.1% and -1.0%, respectively.
VIR support price is $11.28 and resistance is $12.22 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that VIR shares will trade within this expected range on the day.
